What is the Market's View on Mustang Bio Inc (MBIO) Stock's Price and Volume Trends Wednesday?

Mustang Bio Inc (MBIO) stock is down 22.84% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Mustang Bio Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MBIO!

See Full MBIO Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With MBIO Stock Today?

Mustang Bio Inc (MBIO) stock has fallen -1.32% while the S&P 500 is up 0.06% as of 10:29 AM on Wednesday, Aug 16. MBIO has fallen -$0.05 from the previous closing price of $3.80 on volume of 7,564 shares. Over the past year the S&P 500 has gained 3.34% while MBIO has fallen -66.67%. MBIO lost -$10.29 per share in the over the last 12 months. To screen for more stocks like Mustang Bio Inc click here.

More About Mustang Bio Inc

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Click Here to get the full Stock Report for Mustang Bio Inc stock.